



Republic of the Philippines
Department of Health
CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

BID BULLETIN NO. 1
23 March 2021

PROCUREMENT OF OSELTAMIVIR AS PHOSPHATE-REBID
IB No. 2021-056-A

This Bid Bulletin is being issued to announce the new schedule of the Submission and Opening of Bids previously set on 31 March 2021, to amend or modify the posted Bidding Documents in the DOH and PhilGEPS websites, to clarify issues and concerns raised during the Pre-Bidding Conference conducted last 17 March 2021, at the COBAC Conference Room, Ground Floor, Building No. 6, Department of Health and to respond to the query of L. Meyerf Pharma, Inc. (LMPI) for the Procurement of Osetamivir as Phosphate-Rebid under IB No. 2021-056-A. This Bid Bulletin shall form an integral part of the bidding document. Listed below are the corresponding modifications/changes:

1. New Schedule of Activity:

Activity	From	To	Venue
Submission and Opening of Bids	31 March 2021; 9:00 A.M	07 April 2021; 9:00 A.M.	COBAC Conference Room, G/F, Bldg. 6 Department of Health San Lázaro Compound, Rizal Avenue Sta. Cruz, Manila

2. Query raised by LMPI during the Pre-Bidding Conference:

PARTICULAR	Bidder's Inquiry	Response from End-user/ COBAC-A
<p>Section VII. Technical Specifications</p> <p>B. Additional Requirements to be attached to Technical Specifications form arranges, numbered and tabbed as enumerated below:</p> <p>1. Valid and current Certificate Product Registration (CPR) or Valid Extension issued by Philippine Food and Drug Administration (PFDA)</p> <p>xxxxxx</p>	<p>LMPI said that their CPR was expired but they already filed for renewal.</p> <p>LMPI claimed that Food and Drugs Administration (FDA) is not aware on any Issuance regarding extension of validity and/or FDA is not issuing the extension of validity period when registering the CPR.</p>	<p>As per FDA Submission Tracking System, renewal of CPR of LMPI with Document Record (DR) XY-38245 was applied and processed by the FDA. For some reason, the validity of extension being applied by the LMPI was not granted by FDA.</p> <p>Extension of Validity, hence, exists and is being done by FDA, regardless of whether FDA grants or denies the said extension.</p> <p>Thus, the PBD has no changes on this particular requirement, CPR.</p>

3. Section V. Special Conditions of the Contract

FROM	TO
GCC Clause 1 xxx DR. JOSE GERARD BELIMAC OIC, Division Chief Disease Prevention and Control Bureau Building 14, Department of Health Tel No.: 651-7800 local 1700 to 1701 Fax No.: 8711-0380	GCC Clause 1 xxx DR. ANNA CELINA G. GARFIN Division Chief Disease Prevention and Control Bureau Building 14, Department of Health Tel No.: 651-7800 local 1700 to 1701 Fax No.: 8711-0380

All other provisions indicated in the bidding documents which are not affected by this Bid Bulletin shall remain in effect.

For guidance and information of all concerned.



NESTOR F. SANTIAGO, JR., MD, MPHC, MHSA, CESO II
Assistant Secretary of Health
Chairperson, COBAC-A